primary anti-αSN antibody. These controls were used to assess any unspecific interactions from A/G agarose beads. Mass spectrometry (MS): IP samples were dissolved in 6M guanidine HCl, 50mM Tris pH-8.0, 2mM dithiothreitol (DTT), heated at 95°C for 15min, then cooled down and diluted in 50mM NH4HCO3 (pH-7.8). A modified trypsin (Promega) was then added in a 1:100 protease:protein ratio (w/w) and incubated for 2h at 37°C. Proteolysis was stopped by quick cooling in dry ice. Obtained peptides were purified using C18 resin ZipTips (Millipore). Briefly, tips were activated with 70% acetonitrile (ACN), 0.1% trifluoreacetic acid (TFA) and washed three times with 0.1% TFA. Next, the sample was loaded onto resin by gently pipetting back and forth through a tip 20 times, putting flow through back into the sample tube each time. Resin was washed three times with of 0.1% TFA and bound peptides eluted two times by 70% ACN, 0.1% TFA into a new tube. All samples were dried down to approx. 10µL using a vacuum centrifuge. Thereafter samples were analysed on a nanoLC system (Easy-nLC II, ThermoFisherScientific) coupled to an electrospray linear ion trap (LTQ, ThermoFisher Scientific) mass spectrometer. The sample was injected and desalted on a precolumn (2cm, 100µm I.D, 120Å, 5µm C-18A1; Easy column, ThermoFisher Scientific) at a flow rate of 10µL/min for 10min. A picofrit 15-cm fused silica emitter with a 75µm inner diameter and a 375µm outer diameter (New Objective) was used as the analytical column. The emitter was packed in-house with a slurry of reverse-phased ACE C18-AR 2-µm resin (Scantec Nordic) dispersed in methanol using a pressurized packing devise (Proxeon Biosystems). The mobile phases were BufferA (0.1% Formic acid in water) and BufferB (ACN and 0.1% Formic acid). The peptide samples were separated during 40min gradient from 2-55% BufferB at a flow rate of 250nL/min and the MS data was collected in a data dependent manner. The acquisition continuously switches between full MS scan (m/z 300-2000), zoom scan (most intense peak in full scan) and MS/MS scan (most intense peak in zoom scan) where the most intense peak can be picked twice in a time window of 40s and is then put on an exclusion list during a 150s period. The MS/MS data was converted into a combined mgf-file. The mgf-files were searched against H. sapiens database using a X!Tandem search engine. The following settings were used for the database search: peptide mass tolerance of ±0.5Da; fragment mass tolerance of ±0.5Da; Carbamidometyl Cys, or unspecific cleavage, possible post-translational modifications (N-terminal acetylation, N-terminal pyroglutamic acid derived from glutamine, C-terminal amidation, oxidation of methionine and tryptophan, phosphorylation of serine, tyrosine and threonine, deamidation of asparagine and glutamine). A significance threshold of log<-2 was used for individual peptide.
Immunogold labelling and Transmission Electron Microscopy (TEM):
To remove small and medium proteins, the CSF sample was initially filtered through a 100kDa Amicon Ultra-15 Centrifugal Filter Unit (Millipore) and the retained solution was collected for TEM analysis. An aliquot of 3µL from each sample was added to a grid with a glow discharged carbon coated supporting film for 3min. The excess solution was soaked off by a filter paper. The anti-ApoE antibody and the anti-αSN antibody, diluted 1:20 each in 0.1M PBS containing 0.1% normal goat serum (PBG), were incubated for 1.5h. Afterwards, grids were rinsed in PBG and bound antibodies were detected using the secondary goat polyclonal anti-mouse (5nm, anti-ApoE antibody detection) or goat polyclonal anti-rabbit (10nm, anti-αSN antibody detection) antibodies at a final dilution of 1:100 each. Next, sections were rinsed in PBS, distilled water and stained with 1% uranyl acetate in water for 10s and air-dried. The samples were examined in a Hitachi7700 (Tokyo) at 80kV and digital images were taken by a Veleta camera (Olympus).
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE):
To ensure the unbiased data analysis all samples were coded and each single gel include both controls' and patients' samples run randomly. Furthermore, normalization sample, composed of a mixture of several CSF samples for CSF analysis and a mixture of several plasma samples for plasma analysis, was run on each gel. The sample was mixed in 3:1 ratio with a denaturing loading buffer (106mM Tris-HCl, 141mM Tris, 2% lithium dodecyl sulphate (LDS), 10% glycerol, 6% β-mercaptoethanol, 0.51mM EDTA, 0.22mM SERVA Blue G-250, 0.175mM Phenol Red, pH-8.5) and boiled at 95ºC for 5min. Next, samples were separated using a bis-tris acrylamide gel using MES running buffer (50mM Tris, 50mM 2-(N-morpholino)ethanesulfonic acid (MES), 0.1% SDS, 1mM EDTA, pH-7.3). 20µL and 5µL of sample was used for accordingly CSF and plasma analysis. If necessary, the gel was stained using Coomassie Brilliant Blue (CBB) R-250 solution (0.1% CBB R-250/40% methanol/10% glacial acetic acid) and distained using 4%/4% glacial acetic acid/ethanol solution. SDS-PAGE gels were scanned using standard table-top scanner or red channel on Odyssey™ CLx Imaging System (LI-COR). The intensity of protein bands was analysed using ImageJ [1] . Western blotting (WB): After SDS-PAGE, gels were incubated in a transfer buffer (25mM Tris, 192mM glycine, 30% methanol) and 0.45μm pore size Immobilon-P™ PVDF membranes (Millipore) were pre-wetted in methanol. Gels were then assembled with membranes using TE22™ Mini Tank Transfer Unit cassettes (GE Healthcare) and overnight transfer was performed at 4°C. Next, membranes were dried and shortly fixed in 100% methanol. For detection of small proteins, in samples with a low total protein content, a mixture of 3% paraformaldehyde/0.01% glutaraldehyde in PBS was used as a fixative [9] . Between each incubation period, membranes were washed three times in Tris Buffered Saline (TBS, 20mM Tris, 150mM NaCl, pH-7.6) containing 0.1%(v/v) Tween20 (TBS-T). Membranes were blocked during 1h incubation in 5% skim milk at RT. Next, membranes were incubated overnight at 4°C with a primary antibody diluted 1:2000(v/v) in 1% skim milk. Membranes were thereafter incubated for 2h with appropriate HRP-conjugated secondary antibody (Dako) diluted 1:10000(v/v) in 1% skim milk at RT. The signal was developed by a Clarity™ Western ECL Substrate (Bio-Rad), specificity of antibodies was checked (Fig. S1 ) and levels of visualized proteins were estimated by measuring band intensities with ImageJ [1] . When necessary a colorimetric scan was used to visualize the protein ladder. Additionally, since there is no loading control available for the CSF analysis and the total protein content may change due to many factors, correlation analyses between apolipoproteins' levels and both albumin and IgG were performed to ensure that their levels are not changing with the total protein content. Moreover, on all blots from the same cohort, normalization sample, composed of the mixture of several CSF or plasma samples, was used to compare results across blots. Immunohistochemistry (IHC): Human formalin-fixed, paraffin-embedded 5µm section from subjects without neurological disorder (n=2; male, age 77 and male, age 73) or Parkinson's disease (n=2; male, age 78, disease duration 12 years and male, age 75, disease duration 12 years), were obtained from the Brain Bank at Karolinska Institutet. Sections were deparaffinised, rehydrated and a heat-induced epitope retrieval was done in Tris-EDTA buffer (10mM Tris base, 1mM EDTA solution, 0.05% Tween20, pH-9.0) for 20min at 95°C followed by a 10min rinse in cold water.
Sections were washed 4 times in PBS between each incubation period. The endogenous peroxidase activity was quenched for 15min in a mix of 3% hydrogen peroxide and 10% methanol in PBS. One-hour incubation in 5% goat normal serum proceeded overnight incubation with the anti-ApoE antibody in 2.5% goat normal serum at 4°C. Thereafter, sections were incubated with the HRP conjugated antibody in 1% goat normal serum. The peroxidase labelling was visualized with mix of 3,3-diaminobenzidine and nickel (SK-4100, Vector Laboratories) which yielded a blue/grey reaction product. A negative control, omitting the primary antibody, was performed in parallel. Preparation of recombinant αSN monomers, oligomers and fibrils: αSN plasmid vector pET11-D, containing the insert coding human αSN, was expressed in E.coli BL21(DE3) competent cells using an auto-induction method. Cells were harvested by centrifugation and treated with the osmotic shock buffer (20mM Tris-HCl, pH-7.2, 40% sucrose), incubated for 10 min and centrifuged again. Afterwards, the pellet was suspended in ice-cold deionised water, with subsequent addition of saturated MgCl2, and briefly incubated on ice. The periplasmic fraction of the cell lysate was collected and majority of unwanted proteins precipitated by adjusting pH to 3.5 with 1M HCl. Soluble proteins were collected by centrifugation and pH of the obtained supernatant was adjusted to pH-7.5 with 1M NaOH. The solution was filtered and fractionated on a Q-Sepharose column connected to an ÄKTA Explorer system (GE Healthcare) using rising concentration of NaCl. Fractions containing αSN were identified by SDS-PAGE and pulled together. Further, high molecular weight aggregates were removed by filtration through a 30kDa cut-off filter, to obtain only monomeric form of αSN, and analysed with SDS-PAGE to ensure purity. Final solution was dialyzed against deionised water. The αSN concentration was determined using NanoDrop ND-1000 (Thermo Scientific), protein was aliquoted, lyophilized and stored at -20°C. To obtain αSN oligomers, αSN monomers ware dissolved to 12 mg/ml and incubated in an eppendorf shaker at 37°C, 900 rpm for 5 hrs. Insoluble material was removed by centrifugation at room temperature at 16000 x g for 10 min. The supernatant were loaded on Superpose 6 column (GE Healthcare) connected to an ÄKTA Explorer system (GE Healthcare) in PBS buffer at a flowrates of 2 ml/min. Oligomer fractions were collected, concentrated with a 50kDa cut-off spin filter and stored at 4 °C. The recombinant αSN was fibrillated as described before [4] . αSN monomers were dissolved at 1 mg/ml and incubated at 37°C with shaking for 5 days. Obtained samples was centrifuged at room temperature at 16000 x g for 10 min and obtained pellet was suspended in PBS buffer. To obtain unified length on fibrils (pre-formed fibrils, PFF) each sample was briefly sonicated. For aggregation analysis the recombinant αSN, with or without addition of ApoE, was fibrillated at a final concentration of 1mg/mL for αSN and 0.25mg/mL for ApoE with 40μM ThT in a Tecan Spark 10M (Tecan Nordic AB) plate reader at 37°C with 5min shaking and signal readout every 10min. The ThT signal was monitored at 448nm excitation and 485nm emission. Tables   Fig. S1 . Anti-apolipoproteins antibodies specificity using the WB method. Representative autoradiograms (left) and autoradiograms merged with colorimetric scans of the membrane (right) from films obtained after running CSF samples and performing WB procedure against analysed apolipoproteins. Red -residues from a peptide domain observed at least once during the analysis; Green -residues predicted to be difficult to observe by standard techniques; Blue -residues found are chemically modified. anti-αSN antibody (sc-7011-R, Santa Cruz), the goat polyclonal anti-ApoE antibody (178479, EMD Millipore), mouse IgGs, rabbit IgGs, goat IgGs and the protein A/G agarose beads alone. 12 CSF samples were used for this experiment, both from Parkinson's disease cases (n=6, 3/3 males/females, average age 64.67±4.75) and healthy controls (n=6, 3/3 males/females, average age 66.50±1.38). 
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